DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
MicroRNA Alterations in a Tg501 Mouse Model of Prion Disease
20 Pág., MicroRNAs (miRNAs) may contribute to the development and pathology of many neurodegenerative diseases, including prion diseases. They are also promising biomarker candidates due to their stability in body fluids. We investigated miRNA alterations in a Tg501 mouse model of prion diseases that expresses a transgene encoding the goat prion protein (PRNP). Tg501 mice intracranially inoculated with mouse-adapted goat scrapie were compared with age-matched, mock inoculated controls in preclinical and clinical stages. Small RNA sequencing from the cervical spinal cord indicated that miR-223-3p, miR-151-3p, and miR-144-5p were dysregulated in scrapie-inoculated animals before the onset of symptoms. In clinical-stage animals, 23 significant miRNA alterations were found. These miRNAs were predicted to modify the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways including prion disease, extracellular matrix interactions, glutaminergic synapse, axon guidance, and transforming growth factor-beta signaling. MicroRNAs miR-146a-5p (up in cervical spinal cord) and miR-342-3p (down in cervical spinal cord, cerebellum and plasma), both indicated in neurodegenerative diseases earlier, were verified by quantitative real-time polymerase chain reaction (qRT-PCR). Minimal changes observed before the disease onset suggests that most miRNA alterations observed here are driven by advanced prion-associated pathology, possibly limiting their use as diagnostic markers. However, the results encourage further mechanistic studies on miRNA-regulated pathways involved in these neurodegenerative conditions., This research was partially funded by the Spanish Ministerio de Economía y Competitividad (AGL2015-67945-P to J.M.T. and I.M.-B.; AGL2016-78054-R [AEI/FEDER, UE] to J.-M.T. and J.-C.E.); Ministerio de Ciencia e Innovación (RTI2018-098711-B-I00); Instituto de Salud Carlos III (Grant PI17/00949) and Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa”; Instituto Nacional de Investigación y Tecnología Agraria y Agroalimentaria (fellowship INIA-FPI-SGIT-2015-02 to A.M.-M.); Spain-France-Andorra Cooperation Program (POCTEFA), co-funded by the European Regional Development Fund (ERDF) (EFA 148/16 REDPRION); the Government of Aragón (reference group A19-17R) co-financed with FEDER 2014-2020 “Construyendo Europa desde Aragón”, and Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED)., Peer reviewed
Proyecto:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 AGL2015-67945-P
,
AEI RTI2018-098711-B-I00
DOI: http://hdl.handle.net/10261/340373, https://api.elsevier.com/content/abstract/scopus_id/85086685522
HANDLE: http://hdl.handle.net/10261/340373, https://api.elsevier.com/content/abstract/scopus_id/85086685522